The Priority Review

The stream · Daily digest

The stream: Monday, October 19, 2026

9 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 8

  1. DelveInsight reports KRAS inhibitors market to grow positively by 2036

    DelveInsight said the total KRAS inhibitors market size is expected to grow positively by 2036, driven by therapies such as Divarasib (RG6330), Olomorasib (LY3537982) and MK-1084. The company noted the United States accounted for the largest market share in 2025, with 539,400 incident NSCLC cases.

    Source: Company press release (PR Newswire), October 19, 2026

  2. Eli Lilly registers Phase 3 study of EloraTZP in obesity

    The study, NCT07881432 (AMPLIFY-1), was first posted on ClinicalTrials.gov on October 19, 2026. It plans to enroll 2115 participants, start in December 2026, and reach primary completion in October 2029.

    Source: ClinicalTrials.gov registry record, October 19, 2026

  3. Beeline registers Phase 2/3 study of afimetoran in cutaneous lupus erythematosus

    The study, led by Beeline Medicines Corporation, plans to enroll 390 participants and begin in October 2026. It evaluates afimetoran versus placebo over 24 weeks, with a total treatment period of 52 weeks, and aims to assess changes in the CLASI-A skin activity score.

    Source: ClinicalTrials.gov registry record, October 19, 2026

  4. R-Pharm registers Phase 3 study of Goflikicept in pediatric FMF

    The study plans to enroll 18 participants and plans to begin in December 2026, with primary completion projected for May 2029. It aims to evaluate the pharmacokinetics, efficacy, and safety of goflikicept in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever.

    Source: ClinicalTrials.gov registry record, October 19, 2026

  5. Eli Lilly registers Phase 3 study of EloraTZP in obesity and type 2 diabetes

    The study plans to enroll 1000 participants, start in November 2026, and reach primary completion in October 2029. It aims to investigate the efficacy and safety of the eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide in adults with obesity or overweight and type 2 diabetes.

    Source: ClinicalTrials.gov registry record, October 19, 2026

  6. Protagonist posts results of Phase 3 rusfertide study in polycythemia vera

    The study enrolled 293 participants and was completed with primary data collected by February 21, 2025. Results were first posted on ClinicalTrials.gov on October 19, 2026.

    Source: ClinicalTrials.gov results record, October 19, 2026

  7. Johnson & Johnson reports one-year FUZION results for TREMFYA in Crohn's disease

    The company said TREMFYA maintained combined fistula remission through 48 weeks in adults with Crohn's disease and perianal fistula, with 35% remission at Week 48 in the 100 mg q8w group. More than 90% of all randomized patients completed treatment through Week 48, and safety findings were consistent with the established safety profile.

    Source: Company press release (PR Newswire), October 19, 2026

  8. Lilly's Omvoh meets primary endpoint of clinical remission in pediatric ulcerative colitis

    In the single-arm, open-label Phase 3 SHINE-2 study, 81% of 63 pediatric patients achieved clinical response at Week 12 and 50% of responders were in clinical remission at Week 52, meeting the study's primary endpoint. The safety profile through Week 52 was consistent with that seen in adults, with no new safety signals reported.

    Source: Company press release (PR Newswire), October 19, 2026

Approvals · 1

  1. FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer

    On October 19, 2026 the FDA granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient. The approval was based on AZUR-1, a single-arm trial of 154 patients that reported a 47% sustained clinical complete response at 12 months per independent central review.

    Source: FDA approval notification, October 19, 2026